Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab versus adalimumab in biologic-naive moderate-to-severe Crohn's disease
NL-OMON50125Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Ustekinumab arm with Adalimumab arm (2 arms). Primary endpoint: Clinical remission at one year. Started Oct 2018; status: completed.
02
Drugs
ustekinumabadalimumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON50125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50125.